RxDoctor Payments Data

Jorge Mendizabal, MD

Neurology · Corpus Christi, TXNPI 1588771950

Payments from drug & device makers

$87,053in general payments, 2019–2025

Across 479 payments — averaging $181.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$38K
  • Teva Pharmaceuticals USA, Inc.$21K
  • Amgen$21K
  • Pfizer$2K
  • Biogen$763
  • Novartis$555
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$3,2754%
  • Speaking & faculty fees$72,24683%
  • Travel & lodging$3,2274%
  • Food & beverage$8,30410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,053 in reported general payments places this provider in the 85th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$127,755
Medicare patients
428
Services billed
1,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$115,632
BotoxOnabotulinumtoxina88$101,078
Emgality PenGalcanezumab-Gnlm99$74,911
QuliptaAtogepant65$73,526
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$70,750
Nurtec OdtRimegepant Sulfate41$66,417
Aimovig AutoinjectorErenumab-Aooe71$57,271
Glatiramer Acetate13$36,969
BriviactBrivaracetam20$30,722
RexultiBrexpiprazole21$30,237
UbrelvyUbrogepant19$22,017
Galantamine Hbr202$16,788
BelsomraSuvorexant30$12,742
Ajovy AutoinjectorFremanezumab-Vfrm16$11,801
HorizantGabapentin Enacarbil19$10,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Qulipta, Ubrelvy$38,047$196,622172 claims
Neurocrine Biosciences, Inc.Ingrezza$136$115,63212 claims
PfizerNurtec Odt, Dilantin$2,232$71,58564 claims
UCB, Inc.Briviact$426$30,72220 claims
Otsuka America Pharmaceutical, Inc.Rexulti$135$30,23721 claims
Arbor Pharmaceuticals, Inc.Horizant$13$10,32519 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$19$4,98566 claims
Upsher-smith Laboratories LLCTopiramate$16$3,579443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,246 neurology providers in Texas.

Other neurology in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →